|
gptkbp:instance_of
|
gptkb:drug
|
|
gptkbp:bfsLayer
|
5
|
|
gptkbp:bfsParent
|
gptkb:carbamazepine
|
|
gptkbp:activities
|
inhibits voltage-gated sodium channels
|
|
gptkbp:approves
|
gptkb:1994
gptkb:FDA
|
|
gptkbp:brand
|
Lamictal
|
|
gptkbp:category
|
gptkb:C
|
|
gptkbp:clinical_trial
|
Phase III
|
|
gptkbp:contraindication
|
hypersensitivity
severe liver impairment
|
|
gptkbp:developed_by
|
gptkb:Glaxo_Smith_Kline
|
|
gptkbp:dosage_form
|
100-200 mg daily
25-50 mg daily for maintenance
initial dose 25 mg daily
|
|
gptkbp:excretion
|
urine
|
|
gptkbp:formulation
|
gptkb:tablet
extended-release tablet
chewable tablet
dispersible tablet
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
lamotrigine
|
|
gptkbp:ingredients
|
C9 H7 Cl2 N5
|
|
gptkbp:interacts_with
|
gptkb:valproate
gptkb:carbamazepine
oral contraceptives
|
|
gptkbp:is_available_on
|
generic drug
|
|
gptkbp:is_monitored_by
|
skin reactions
liver function tests
serum levels
|
|
gptkbp:is_used_for
|
gptkb:psychologist
bipolar disorder
|
|
gptkbp:lifespan
|
25 hours
|
|
gptkbp:manager
|
oral
|
|
gptkbp:metabolism
|
liver
|
|
gptkbp:provides_information_on
|
gptkb:National_Institute_for_Health_and_Care_Excellence
gptkb:American_Psychiatric_Association
gptkb:American_Academy_of_Neurology
|
|
gptkbp:side_effect
|
gptkb:historical_event
anxiety
dizziness
fatigue
headache
nausea
vomiting
rash
ataxia
drowsiness
insomnia
blurred vision
suicidal thoughts
tremor
aseptic meningitis
|